JP2018520667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520667A5 JP2018520667A5 JP2017564407A JP2017564407A JP2018520667A5 JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5 JP 2017564407 A JP2017564407 A JP 2017564407A JP 2017564407 A JP2017564407 A JP 2017564407A JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- light chain
- variable region
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078441A JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173330P | 2015-06-09 | 2015-06-09 | |
| US62/173,330 | 2015-06-09 | ||
| PCT/US2016/036735 WO2016201124A2 (en) | 2015-06-09 | 2016-06-09 | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Division JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520667A JP2018520667A (ja) | 2018-08-02 |
| JP2018520667A5 true JP2018520667A5 (enExample) | 2020-05-28 |
| JP7000162B2 JP7000162B2 (ja) | 2022-02-10 |
Family
ID=57504187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564407A Expired - Fee Related JP7000162B2 (ja) | 2015-06-09 | 2016-06-09 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501559B2 (enExample) |
| EP (1) | EP3307319A4 (enExample) |
| JP (2) | JP7000162B2 (enExample) |
| KR (1) | KR20180023949A (enExample) |
| CN (1) | CN108289950B (enExample) |
| AU (1) | AU2016274767B2 (enExample) |
| CA (1) | CA2988768A1 (enExample) |
| HK (1) | HK1252653A1 (enExample) |
| IL (2) | IL281396B (enExample) |
| MX (1) | MX2017015666A (enExample) |
| SG (1) | SG10202110887PA (enExample) |
| WO (1) | WO2016201124A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| CA2988768A1 (en) | 2015-06-09 | 2016-12-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| CA3091143A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan-Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| CN112189018A (zh) | 2018-04-20 | 2021-01-05 | 汉诺威医学院 | 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞 |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| US12084500B2 (en) * | 2019-01-23 | 2024-09-10 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| WO2020160189A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Oncology, Inc. | Multispecific binding proteins |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| WO2020191365A1 (en) * | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| MX2022000081A (es) * | 2019-07-03 | 2022-04-27 | Regeneron Pharma | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso. |
| EP3786178A1 (en) * | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| CN111690617B (zh) * | 2020-05-18 | 2023-05-02 | 李欣 | 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用 |
| CN114457165A (zh) * | 2022-04-13 | 2022-05-10 | 深圳荻硕贝肯精准医学有限公司 | 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1998034957A1 (en) | 1997-02-11 | 1998-08-13 | Immunomedics, Inc. | STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| AU783502B2 (en) | 1999-11-24 | 2005-11-03 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | PROCESS FOR PURIFYING ANTIBODY |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011062560A1 (en) | 2009-11-19 | 2011-05-26 | National University Of Singapore | Method for producing t cell receptor-like monoclonal antibodies and uses thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| DK3030581T3 (da) * | 2013-08-07 | 2021-04-12 | Affimed Gmbh | Antistofbindingssteder, der er specifikke for egfrviii |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| WO2015199618A1 (en) | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| CA2988768A1 (en) | 2015-06-09 | 2016-12-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
-
2016
- 2016-06-09 CA CA2988768A patent/CA2988768A1/en active Pending
- 2016-06-09 AU AU2016274767A patent/AU2016274767B2/en not_active Ceased
- 2016-06-09 HK HK18111960.3A patent/HK1252653A1/zh unknown
- 2016-06-09 IL IL281396A patent/IL281396B/en unknown
- 2016-06-09 SG SG10202110887PA patent/SG10202110887PA/en unknown
- 2016-06-09 MX MX2017015666A patent/MX2017015666A/es unknown
- 2016-06-09 US US15/735,133 patent/US10501559B2/en active Active
- 2016-06-09 KR KR1020187000659A patent/KR20180023949A/ko not_active Ceased
- 2016-06-09 WO PCT/US2016/036735 patent/WO2016201124A2/en not_active Ceased
- 2016-06-09 CN CN201680046924.2A patent/CN108289950B/zh not_active Expired - Fee Related
- 2016-06-09 JP JP2017564407A patent/JP7000162B2/ja not_active Expired - Fee Related
- 2016-06-09 EP EP16808304.6A patent/EP3307319A4/en not_active Withdrawn
-
2017
- 2017-11-30 IL IL256035A patent/IL256035A/en unknown
-
2019
- 2019-10-28 US US16/665,708 patent/US11168150B2/en active Active
-
2021
- 2021-05-06 JP JP2021078441A patent/JP2021106623A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520667A5 (enExample) | ||
| JP7328658B2 (ja) | 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用 | |
| CN108064236B (zh) | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| KR102701479B1 (ko) | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 | |
| JP2020508655A5 (enExample) | ||
| BRPI0611194B1 (pt) | Moléculas de ligação anti-cd16 | |
| JP2017526370A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| CN109715661B (zh) | 抗干扰素-γ的抗体及其应用 | |
| JP2012501670A5 (enExample) | ||
| KR20130010117A (ko) | Ｂ７―ｈ３에 반응성인 항체, 면역학적으로 활성인 이들의 단편 및 이들의 사용법 | |
| JP2011509245A5 (enExample) | ||
| CN110678484B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
| Staelens et al. | Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains | |
| JP2019535306A5 (enExample) | ||
| JP2019515648A (ja) | ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用 | |
| JP2016518333A5 (enExample) | ||
| CA3157611A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| AU2015336931B2 (en) | CD83 binding proteins and uses thereof | |
| CA3227160A1 (en) | Anti-hla-g antibodies | |
| JP2016529213A5 (enExample) | ||
| TW202233677A (zh) | Bcma/taci抗原結合分子 | |
| JPWO2022111425A5 (enExample) | ||
| Kapelski et al. | Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a Pf MSP4-specific antibody |